Epic Sciences, Inc.
http://www.epicsciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Epic Sciences, Inc.
Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
Cooper Buys Cook’s Reproductive Health Business For $875M
Cooper expects the addition of Cook’s products and staff will allow it to reach more patients, especially in the fast-growing Asia-Pacific fertility market.
Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
Company Information
- Industry
- Biotechnology
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Digital Health
- Artificial Intelligence